Home › Posts tagged Epidermal Growth Factor Receptor (EGFR)
Blog Archives

The Clinical and Economic Impact of Inaccurate EGFR Mutation Tests in the Treatment of Metastatic Non-Small Cell Lung Cancer

Posted on by by Posted in Companion Test, Diagnostic, Personalized Medicine, PubMed Entry, Thasso Post, Theragenomic Medicine No Comments ↓

June 30, 2017 – The below citation from PubMed addresses an vey important issue associated with genetic testing in theragenomic and personalized medicine. It is the question if the genetic test used to stage, classify, or determine treatability of a disease with a given drug is accurate.

…

Read more ›

Tags: , , , , , , , ,

This is it: First blood test to detect EGFR gene mutations in NSCLC

Posted on by by Posted in Companion Test, Diagnostic, Personalized Medicine, Thasso Post, Theragenomic Medicine 1 Comment ↓

June 03, 2016 – This is a huge step in the application of theragenomic medicine in cancer patients in the quest to deliver highly individualized health care for patients. Thus, on June 01, the American Food & Drug Administration (FDA) approved the cobas EGFR Mutation Test v2,

…

Read more ›

Tags: , , , , , , , , , , ,

Osimertinib (Tagrissa) approved for non-smal cell lung cancer (NSCLC) patient subgroup carrying the EGFR T790M mutation

Posted on by by Posted in Allelische Variante, Genetic Predisposition, Personalized Medicine, Pharmacogenetics, Regulatory Approval, Targeted Therapy, Thasso Post, Theragenomic Medicine, Uncategorized No Comments ↓

February 07, 2016 – The European Commission has approved once-daily Osimertinib (Tagrissa) for the treatment of patients with locally advanced or metastatic non-small-cell lung cancer (NSCLC) that is positive for the epidermal growth-factor receptor (EGFR) T790M mutation. This follows a positive review in December 2015.

…

Read more ›

Tags: , , , , , , ,

Necitumumab (Portrazza) approved for the treatment of advanced squamous non-small cell lung cancer (NSCLC)

Posted on by by Posted in New Drug Approval, Thasso Post, Theragenomic Medicine No Comments ↓

November 28, 2015 – The American Food and Drug Administration (FDA) just approved Necitumumab (Portrazza) in combination with two forms of chemotherapy to treat patients with advanced (metastatic) squamous non-small cell lung cancer (NSCLC) who have not previously received medication specifically for treating their advanced lung cancer.

…

Read more ›

Tags: , , , , , , ,

Theragenomic medicine: FDA approves Osimertinib (Tagrisso) to treat patients with non-small cell lung cancer (NSCLC) who carry the EGFR mutation T790M

Posted on by by Posted in Genetic Predisposition, New Drug Approval, Targeted Therapy, Thasso Post, Theragenomic Medicine No Comments ↓

November 14, 2015 – The American Food and Drug Administration (FDA) just granted accelerated approval for an oral medication to treat patients with advanced non-small cell lung cancer (NSCLC). Osimertinib (Tagrisso) was approved for patients whose tumors have a specific epidermal growth factor receptor (EGFR) mutation (T790M) and whose disease has gotten worse after treatment with other EGFR-blocking therapy.

…

Read more ›

Tags: , , , , , , ,

FDA Approves Companion Genetic Diagnostic Test for Erlotinib [Tarceva] in NSCLC

Posted on by by Posted in Allelische Variante, Genetic Predisposition, Personalized Medicine, Thasso Post No Comments ↓

May 14, 2013 – The US Food and Drug Administration (FDA) today announced the approval of the cobas EGFR Mutation Test, a companion diagnostic for the cancer drug Erlotinib (Tarceva). This is the first FDA-approved companion diagnostic that can detect epidermal growth factor receptor (EGFR) gene mutations,

…

Read more ›

Tags: , , , , , , , , , ,

thasso: donate

thasso: conditions

thasso: newest tweets

 

thasso: recent comments

thasso post: magazine

View my Flipboard Magazine.

thasso: categories

thasso: archives

thasso: simple chat

You must be a registered user to participate in this chat.

RSS random genetics

RSS random science

  • Discovery of life in solid rock deep beneath sea may inspire new search for life on Mars April 2, 2020
    Newly discovered single-celled creatures living deep beneath the seafloor have provided clues about how to find life on Mars. These bacteria were discovered living in tiny cracks inside volcanic rocks after researchers perfected a new method cutting rocks into ultrathin slices to study under a microscope. Researchers estimate that the rock cracks are home to […]
  • Geneticists are bringing personal medicine closer to recently admixed individuals April 2, 2020
    A new study in Nature Communications proposes a method to extend polygenic scores, the estimate of genetic risk factors and a cornerstone of the personalized medicine revolution, to individuals with multiple ancestral origins. The study was led by Dr. Davide Marnetto from the Institute of Genomics of the University of Tartu, Estonia and coordinated by […]
  • Breast density, microcalcifications, and masses may be heritable traits April 2, 2020
    An analysis of a large Swedish cohort revealed that breast density, microcalcifications, and masses are heritable features, and that breast density and microcalcifications were positively associated with a genetic predisposition to breast cancer, according to a study published in Cancer Research, a journal of the American Association for Cancer Research.
  • Impacts of cover crop planting dates on soil properties after 4 years April 2, 2020
    Low biomass production limits cover crop effects on soils.
  • A next-generation sensor network for tracking small animals April 2, 2020
    A newly developed wireless biologging network (WBN) enables high-resolution tracking of small animals, according to a study published April 2 in the open-access journal PLOS Biology by Simon Ripperger of the Leibniz Institute for Evolution and Biodiversity Science, and colleagues.
Top